Arrowhead Pharmaceuticals’ (ARWR) “Buy” Rating Reiterated at HC Wainwright

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $100.00 target price on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 59.85% from the company’s current price.

A number of other analysts also recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and set a $110.00 target price (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. Chardan Capital increased their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday. The Goldman Sachs Group upped their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 7th. Finally, Royal Bank Of Canada raised their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $81.67.

Arrowhead Pharmaceuticals Trading Down 3.0%

ARWR stock opened at $62.56 on Tuesday. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. The company has a market cap of $8.76 billion, a price-to-earnings ratio of 40.89 and a beta of 1.21. The business has a fifty day simple moving average of $66.99 and a 200-day simple moving average of $44.15. Arrowhead Pharmaceuticals has a 52 week low of $9.57 and a 52 week high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The firm had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. Arrowhead Pharmaceuticals’s revenue was up 10461.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.39) EPS. On average, equities research analysts expect that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

Insider Activity

In related news, COO Patrick O’brien sold 49,493 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the sale, the chief operating officer owned 474,908 shares in the company, valued at approximately $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mauro Ferrari sold 7,530 shares of the company’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $70.00, for a total transaction of $527,100.00. Following the completion of the sale, the director directly owned 69,053 shares in the company, valued at $4,833,710. This represents a 9.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 510,836 shares of company stock worth $33,603,060 over the last quarter. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Arrowhead Pharmaceuticals by 3.3% during the third quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock valued at $553,077,000 after buying an additional 510,798 shares in the last quarter. Avoro Capital Advisors LLC raised its position in shares of Arrowhead Pharmaceuticals by 2.8% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock valued at $375,941,000 after acquiring an additional 300,000 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Arrowhead Pharmaceuticals by 4.3% during the 4th quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company’s stock valued at $216,799,000 after acquiring an additional 133,921 shares in the last quarter. Marshall Wace LLP lifted its stake in Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock worth $34,065,000 after purchasing an additional 2,096,238 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Arrowhead Pharmaceuticals by 3,142.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after purchasing an additional 2,017,489 shares during the period. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.